Literature DB >> 11779514

Usefulness of lipoprotein changes during acute coronary syndromes for predicting postdischarge lipoprotein levels.

Yaakov Henkin1, Eugene Crystal, Yury Goldberg, Michael Friger, Jonathan Lorber, Irene Zuili, Shraga Shany.   

Abstract

The aim of our study was to evaluate the lipoprotein changes that occur during acute coronary events, and to determine the lipoprotein threshold levels that identify patients who require future statin therapy. Lipoprotein levels were measured at admission, at 6 hours, the morning after admission, before discharge, and 3 months after discharge in patients with myocardial infarction and unstable angina. Patients with myocardial infarction on thrombolytic therapy (n = 63) and patients with unstable angina (n = 33) had a decrease in low-density lipoprotein (LDL) cholesterol levels < or = 24 hours after admission (-12 +/- 20% and -6 +/- 23%, respectively), but these levels returned to baseline before discharge. In patients with myocardial infarction who did not receive thrombolytic therapy (n = 37), the decrease was more gradual and peaked before hospital discharge (-7 +/- 19%). There was good correlation between LDL cholesterol levels at admission and after discharge, especially in normotriglyceridemic patients. Over 90% of patients with LDL cholesterol > or = 125 mg/dl on the morning after admission were candidates for statin therapy after discharge. Thus, the need for future statin therapy can be predicted with fair reliability during the initial 24 hours after admission. However, elevated baseline triglyceride levels significantly affect these LDL cholesterol changes and complicate prediction of long-term lipoprotein levels.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11779514     DOI: 10.1016/s0002-9149(01)02154-3

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

Review 1.  Consensus statement on management of dyslipidemia in Indian subjects.

Authors:  K Sarat Chandra; Manish Bansal; Tiny Nair; S S Iyengar; Rajeev Gupta; Subhash C Manchanda; P P Mohanan; V Dayasagar Rao; C N Manjunath; J P S Sawhney; Nakul Sinha; A K Pancholia; Sundeep Mishra; Ravi R Kasliwal; Saumitra Kumar; Unni Krishnan; Sanjay Kalra; Anoop Misra; Usha Shrivastava; Seema Gulati
Journal:  Indian Heart J       Date:  2014-12-24

Review 2.  Lipid Biomarkers for Risk Assessment in Acute Coronary Syndromes.

Authors:  Jeffrey W Meeusen; Leslie J Donato; Allan S Jaffe
Journal:  Curr Cardiol Rep       Date:  2017-06       Impact factor: 2.931

Review 3.  Lipid-lowering therapies in the management of acute coronary syndromes.

Authors:  Lori Mosca; Angelo Biviano
Journal:  Curr Cardiol Rep       Date:  2002-07       Impact factor: 2.931

Review 4.  The evaluation and management of dyslipidemia and impaired glucose metabolism during acute coronary syndromes.

Authors:  Abhinav Goyal; John L Petersen; Kenneth W Mahaffey
Journal:  Curr Cardiol Rep       Date:  2004-07       Impact factor: 2.931

5.  Changes in triglyceride, HDL-C, and non-HDL-C levels in patients with acute coronary syndrome.

Authors:  Péter Koncsos; Péter Fülöp; Imre Juhász; Klára Bíró; László Márk; Gábor Simonyi; György Paragh
Journal:  Wien Klin Wochenschr       Date:  2016-07-05       Impact factor: 1.704

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.